Stocks › REGN
REGENERON PHARMACEUTICALS, INC.
REGN·Nasdaq·
United States·USD
$920.69
-2.65 (-0.29%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
REGN
REGENERON PHARMACEUTICALS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
REGNS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of REGN by members of U.S. Congress · 244 on record · 15 in the last 12 months
Whale Activity
Position changes in REGN reported for 2026-09-30 by 1523 institutional filers
- Increased561
- New192
- Held178
- Decreased443
- Closed87
- No prior filing62
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 8.8M | $6.71B | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.5M | $4.95B | decreased |
| STATE STREET CORP | 4.9M | $3.70B | increased |
| DODGE & COX | 4.8M | $3.62B | decreased |
| Invesco Ltd. | 3.7M | $2.82B | decreased |
| FRANKLIN TEMPLETON INC | 3.0M | $2.75B | increased |
| JPMORGAN CHASE & CO | 3.3M | $2.48B | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.1M | $2.36B | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6M | $1.99B | increased |
| Nuveen, LLC | 2.0M | $1.48B | decreased |
| LOOMIS SAYLES & CO L P | 1.7M | $1.30B | decreased |
| MORGAN STANLEY | 1.4M | $1.04B | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by REGN insiders, by quarter · Form 4
Recent Insider Transactions
7,024 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −93 | $949.69 | $88K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −74 | $950.61 | $70K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −671 | $953.69 | $640K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −584 | $961.45 | $561K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −506 | $959.45 | $485K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −346 | $956.70 | $331K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −340 | $964.36 | $328K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −313 | $955.48 | $299K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −313 | $954.45 | $299K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −298 | $951.75 | $284K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −295 | $962.70 | $284K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −257 | $960.65 | $247K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −255 | $963.60 | $246K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −244 | $958.27 | $234K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −220 | $952.75 | $210K | Nov 17, 2026 | Form 4 ↗ |
| MURPHY ANDREW JCo-Chief Scientific Officer | Sale | −202 | $957.53 | $193K | Nov 17, 2026 | Form 4 ↗ |
| SING GEORGE LDirector · Director | Sale | −465 | $958.11 | $446K | Nov 17, 2026 | Form 4 ↗ |
| SING GEORGE LDirector · Director | Sale | −359 | $957.49 | $344K | Nov 17, 2026 | Form 4 ↗ |
| SING GEORGE LDirector · Director | Sale | −176 | $956.96 | $168K | Nov 17, 2026 | Form 4 ↗ |
| McCourt MarionEVP Commercial | Sale | −66 | $959.46 | $63K | Nov 16, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding REGN · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.3M | $2.04B | 0.09% | Jun 30, 2026 |
| Dodge & Cox Stock Fund Dodge & Cox Funds | 3.1M | $1.95B | 1.64% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 2.6M | $1.61B | 0.10% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 2.2M | $1.36B | 0.28% | Jun 30, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 1.3M | $1.04B | 0.12% | Aug 31, 2026 |
| Putnam Large Cap Value Fund | 1.2M | $878.6M | 1.59% | Jul 31, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 1.4M | $857.0M | 0.10% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 1.1M | $817.7M | 2.14% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 1.2M | $755.1M | 0.10% | Jun 30, 2026 |
| VANGUARD MID-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $696.0M | 0.31% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list REGN's shares (CUSIP 75886F107), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming regeneron pharmaceuticals as client
- CRANE STRATEGIESREGENERON PHARMACEUTICALS, INC. · 2026 Q3 · BUD$50K
Filing ↗ - REGENERON PHARMACEUTICALS, INCREGENERON PHARMACEUTICALS, INC · 2026 Q3 · CPT, TRD, TAX, HCR$590K
Filing ↗ - BGR GOVERNMENT AFFAIRSREGENERON PHARMACEUTICALS, INC. · 2026 Q3 · HCR$90K
Filing ↗ - ARNOLD & PORTER KAYE SCHOLER LLPREGENERON PHARMACEUTICALS, INC. · 2026 Q3 · HCR$10K
Filing ↗ - CHECKMATE GOVERNMENT RELATIONSREGENERON PHARMACEUTICALS INC. · 2026 Q3 · HCR$90K
Filing ↗
Government Contracts
Federal awards to regeneron pharmaceuticals · USAspending
$1.25BAwarded · 2 contracts on record
U.S. Patents
Recent USPTO applications naming REGENERON PHARMACEUTICALS, INC.
No USPTO patent applications found for REGENERON PHARMACEUTICALS, INC..
Annual Financials
From REGN's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B |
| Operating income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B |
| Net income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B |
| Diluted EPS | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 |
| Operating cash flow | $4.98B | $4.42B | $4.59B | $5.01B | $7.08B |
| Cash and equivalents | $3.12B | $2.49B | $2.73B | $3.11B | $2.89B |
| Total assets | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B |
| Total liabilities | $9.30B | $8.41B | $7.11B | $6.55B | $6.67B |
| Shareholders' equity | $31.26B | $29.35B | $25.97B | $22.66B | $18.77B |
As REGENERON PHARMACEUTICALS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 4, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in REGN's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsOct 30, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.02, 8.01Material agreement · Results of operations · Other eventsOct 6, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeSep 30, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 30, 2026
EDGAR ↗ - 8-K · Items 2.02Results of operationsJul 6, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 17, 2026
EDGAR ↗
About REGENERON PHARMACEUTICALS, INC.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersTARRYTOWN, NY
IncorporatedNY
SEC CIK0000872589 ↗
Former namesREGENERON PHARMACEUTICALS INC






